Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined. Objectives. This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide fo...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/404396 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551612324773888 |
|---|---|
| author | Hamid Reza Mirzaei Parisa Sabet Rasekh Fatemeh Nasrollahi Parto Sabet Rasekh Zahra Akbari Tirabad Hamid Reza Moein Taban Ghaffari Pour Parastoo Hajian |
| author_facet | Hamid Reza Mirzaei Parisa Sabet Rasekh Fatemeh Nasrollahi Parto Sabet Rasekh Zahra Akbari Tirabad Hamid Reza Moein Taban Ghaffari Pour Parastoo Hajian |
| author_sort | Hamid Reza Mirzaei |
| collection | DOAJ |
| description | Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined. Objectives. This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide followed by docetaxel in node-positive breast cancer. Methods. All Patients first received 4 cycles of epirubicin (100 mg/m2) and cyclophosphamide (600 mg/m2) at 2-week interval then followed by docetaxel (100 mg/m2) at 2-week interval for 4 cycles, with daily Pegfilgrastim (G-CSF) that was administered in all patients on days 3–10 after each cycle of epirubicin and cyclophosphamide infusion. Results. Fifty-eight patients with axillary lymph node-positive breast cancer were enrolled in the study, of whom 42 (72.4%) completed the regimen. There were two toxicity-related deaths, one patient due to grade 4 febrile neutropenia and the other due to congestive heart failure. Grade 3/4 neutropenia and febrile neutropenia were 13.8% and 5.1%. The most common grade 3/4 nonhematological complications were as follows: skin-nail disorders (48.3%), hand-foot syndrome (34.4%), paresthesia (38%), arthralgia (27.5%), and paresis (24.1%). Conclusions. Dose-dense epirubicin and cyclophosphamide followed by docetaxel with G-CSF support are not feasible, and it is not recommended for further investigation. |
| format | Article |
| id | doaj-art-842b0b96ff3d438890a66539e80cea8d |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-842b0b96ff3d438890a66539e80cea8d2025-02-03T06:01:00ZengWileyInternational Journal of Breast Cancer2090-31702090-31892013-01-01201310.1155/2013/404396404396Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast CancerHamid Reza Mirzaei0Parisa Sabet Rasekh1Fatemeh Nasrollahi2Parto Sabet Rasekh3Zahra Akbari Tirabad4Hamid Reza Moein5Taban Ghaffari Pour6Parastoo Hajian7Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, IranDepartment of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, IranDepartment of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, IranDepartment of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, IranDepartment of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, IranDepartment of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, IranDepartment of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, IranDepartment of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, IranBackground. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined. Objectives. This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide followed by docetaxel in node-positive breast cancer. Methods. All Patients first received 4 cycles of epirubicin (100 mg/m2) and cyclophosphamide (600 mg/m2) at 2-week interval then followed by docetaxel (100 mg/m2) at 2-week interval for 4 cycles, with daily Pegfilgrastim (G-CSF) that was administered in all patients on days 3–10 after each cycle of epirubicin and cyclophosphamide infusion. Results. Fifty-eight patients with axillary lymph node-positive breast cancer were enrolled in the study, of whom 42 (72.4%) completed the regimen. There were two toxicity-related deaths, one patient due to grade 4 febrile neutropenia and the other due to congestive heart failure. Grade 3/4 neutropenia and febrile neutropenia were 13.8% and 5.1%. The most common grade 3/4 nonhematological complications were as follows: skin-nail disorders (48.3%), hand-foot syndrome (34.4%), paresthesia (38%), arthralgia (27.5%), and paresis (24.1%). Conclusions. Dose-dense epirubicin and cyclophosphamide followed by docetaxel with G-CSF support are not feasible, and it is not recommended for further investigation.http://dx.doi.org/10.1155/2013/404396 |
| spellingShingle | Hamid Reza Mirzaei Parisa Sabet Rasekh Fatemeh Nasrollahi Parto Sabet Rasekh Zahra Akbari Tirabad Hamid Reza Moein Taban Ghaffari Pour Parastoo Hajian Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer International Journal of Breast Cancer |
| title | Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer |
| title_full | Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer |
| title_fullStr | Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer |
| title_full_unstemmed | Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer |
| title_short | Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer |
| title_sort | dose dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node positive breast cancer |
| url | http://dx.doi.org/10.1155/2013/404396 |
| work_keys_str_mv | AT hamidrezamirzaei dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer AT parisasabetrasekh dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer AT fatemehnasrollahi dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer AT partosabetrasekh dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer AT zahraakbaritirabad dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer AT hamidrezamoein dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer AT tabanghaffaripour dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer AT parastoohajian dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer |